Get the Stockscreener App
1.97
1.01%
-0.02
After Hours:
1.93
-0.04
-2.03%
Adial Pharmaceuticals Inc stock is traded at $1.97, with a volume of 143.35K.
It is down -1.01% in the last 24 hours and down -42.48% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
See More
Previous Close:
$1.99
Open:
$1.98
24h Volume:
143.35K
Relative Volume:
2.40
Market Cap:
$2.19M
Revenue:
-
Net Income/Loss:
$-6.07M
P/E Ratio:
-0.3408
EPS:
-5.78
Net Cash Flow:
$-7.34M
1W Performance:
-22.13%
1M Performance:
-42.48%
6M Performance:
-77.39%
1Y Performance:
-89.77%
1-Day Range:
$1.89
$2.10
1-Week Range:
$1.88
$2.6256
52-Week Range:
$1.88
$30.25
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
1.97 | 2.21M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Adial Pharmaceuticals signs framework deal with Molteni for Europe By Investing.com - Investing.com Canada
Adial Pharmaceuticals signs framework deal with Molteni for Europe - Investing.com South Africa
Adial Pharmaceuticals (ADIL) Plans European Expansion for AD04 w - GuruFocus
Adial Pharmaceuticals signs exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe - marketscreener.com
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks
Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones - TradingView
Adial (NASDAQ: ADIL) outlines AD04 Europe deal framework with Molteni - Stock Titan
Adial Pharmaceuticals, Inc. Enters into A Collaboration Framework Agreement with Molteni Farmaceutici - marketscreener.com
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - ADVFN Ltd
Adial Pharmaceuticals, IncWarrant (NQ: ADILW - The Chronicle-Journal
Adial Pharmaceuticals Secures Exchange Listing Amid Regulatory Tailwinds - AD HOC NEWS
ADIL Should I Buy - Intellectia AI
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 87.7% - Defense World
ADIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus
Key facts: Adial Pharmaceuticals meets Nasdaq bid requirement; advances AD04 to Phase 3 trial - TradingView
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - TipRanks
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Bitget
Adial Pharmaceuticals regains full compliance with Nasdaq listing requirement - marketscreener.com
Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView
Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement - TradingView
Adial Pharmaceuticals (ADIL) regains Nasdaq compliance, highlights AD04 Phase 3 path - Stock Titan
Adial cleared by Nasdaq after 10 days with shares at $1 or more - Stock Titan
Adial Pharmaceuticals eyes single pivotal trial path for AD04 - Investing.com India
Adial Pharmaceuticals eyes single pivotal trial path for AD04 By Investing.com - Investing.com Australia
Adial Pharmaceuticals stock rises on FDA policy shift By Investing.com - Investing.com South Africa
Adial Pharmaceuticals stock rises on FDA policy shift - Investing.com
Adial Pharmaceuticals (ADIL) Sees Potential in FDA's New Approva - GuruFocus
Portfolio Shifts: Can Adial Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Volume & Consistent Profit Alerts - baoquankhu1.vn
ADIL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Adial Pharmaceuticals to Present at Healthcare Conference - National Today
Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight Alkermes, Teva Pharma, Biocorrx, Inc., Adial Pharma, ADDEX THERAPEUTICS - Mena FN
Fund Flows: Whats the beta of Adial Pharmaceuticals Inc stockCPI Data & Technical Entry and Exit Alerts - baoquankhu1.vn
Armistice Capital, Steven Boyd report 9.99% stake in ADIL (NASDAQ: ADIL) - Stock Titan
Adial Pharmaceuticals to Present at Oppenheimer Conference - Intellectia AI
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Addiction-focused Adial Pharma to speak at Oppenheimer investor conference - Stock Titan
Litchfield Hills Research Estimates ADIL FY2025 Earnings - Defense World
ADIL Technical Analysis & ETF Price Forecast - Intellectia AI
Can Adial Pharmaceuticals Inc. outperform under higher oil pricesEarnings Growth Summary & Low Risk Entry Point Tips - mfd.ru
Buyback Watch: Whats the beta of Adial Pharmaceuticals Inc stockSell Signal & Community Consensus Picks - baoquankhu1.vn
Will Adial Pharmaceuticals Inc. stock benefit from commodity pricesJuly 2025 Chart Watch & High Accuracy Swing Trade Signals - mfd.ru
Will Adial Pharmaceuticals Inc. benefit from geopolitical trends2025 Macro Impact & Growth Focused Entry Point Reports - mfd.ru
Market Leaders: Whats the fair value of Adial Pharmaceuticals Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Why did Adial Pharmaceuticals stock plunge over 20% after hours today? - MSN
Why Is Adial Pharmaceuticals Stock (ADIL) Down Today? - TipRanks
Key facts: Adial Pharmaceuticals to execute reverse stock split; supports FDA trial - TradingView
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):